Company Overview

Oragenics, Inc. is a U.S.-based biotechnology company focused on the development of intranasal therapeutics for neurological and infectious diseases. The company operates primarily within the biopharmaceutical and neuroscience drug development industries. Its core strategy centers on leveraging proprietary intranasal delivery technologies to enable non-invasive drug administration targeting the central nervous system.

Historically, Oragenics was founded in 1996 and initially focused on oral health probiotics and dental therapeutics. Over time, the company exited its legacy dental business and strategically repositioned itself as a neuroscience-focused biotechnology company. This evolution culminated in a pipeline centered on intranasal drug candidates designed to address conditions with significant unmet medical needs, particularly traumatic brain injury.

Business Operations

Oragenics operates as a single-reportable-segment biotechnology company, generating no significant commercial revenue and primarily funded through equity financing and strategic transactions. Its operations are focused on research and development, clinical trials, regulatory preparation, and intellectual property management related to intranasal therapeutics.

The company’s lead program is ONP-002, an intranasal neuroprotective drug candidate being developed for the treatment of mild traumatic brain injury (mTBI), including concussions. Oragenics controls proprietary intranasal delivery technology and maintains a portfolio of patents and licensed rights supporting its development programs. The company does not currently maintain manufacturing or commercial sales operations and relies on third-party vendors and clinical research organizations.

Strategic Position & Investments

Oragenics’ strategic direction is centered on advancing ONP-002 through clinical development while evaluating additional intranasal applications of neuroactive compounds. The company has emphasized capital-efficient development, regulatory alignment with U.S. authorities, and potential partnering opportunities to support later-stage development and commercialization.

The company has made targeted investments in intellectual property and formulation technologies rather than broad acquisitions. Oragenics has historically divested non-core assets, including its former oral care businesses, to concentrate resources on neuroscience drug development. Its strategy reflects a focus on emerging neurological therapies, particularly those suitable for rapid administration in acute care or field settings.

Geographic Footprint

Oragenics is headquartered in the United States, with its principal executive offices located in Florida. The company’s operations are primarily domestic, with research oversight, corporate management, and regulatory strategy centered in the U.S. market.

While Oragenics does not maintain physical international offices, its clinical development strategy and intellectual property protections extend to multiple jurisdictions. The company’s long-term market focus includes North America and other developed healthcare markets where traumatic brain injury treatment represents a significant clinical and economic burden.

Leadership & Governance

Oragenics is led by an executive team with experience in biotechnology development, capital markets, and corporate restructuring. Leadership emphasizes disciplined capital allocation, regulatory-focused development, and advancing a narrowly defined clinical pipeline.

Key executives include:

• Janet Huffman – Chief Executive Officer and President
• Michael Sullivan – Chief Financial Officer
• Alan Joslyn – Chairman of the Board
• James Kelly – Director

The board and management team oversee strategy with a focus on shareholder value creation through clinical advancement, potential partnerships, and long-term value realization from its intranasal drug platform.